Abstract

Mesenchymal stromal cells (MSCs) represent a key component of bone marrow (BM) microenvironment and display immune-regulatory properties. We performed a detailed analysis of biological/functional properties of BM-MSCs derived from 33 pediatric patients affected by primary immune-deficiencies (PID-MSCs): 7 Chronic Granulomatous Disease (CGD), 15 Wiskott-Aldrich Syndrome (WAS), 11 Severe Combined Immunodeficiency (SCID). Results were compared with MSCs from 15 age-matched pediatric healthy-donors (HD-MSCs). Clonogenic and proliferative capacity, differentiation ability, immunophenotype, immunomodulatory properties were analyzed. WB and RT-qPCR for CYBB, WAS and ADA genes were performed. All PID-MSCs displayed clonogenic and proliferative capacity, morphology and immunophenotype comparable with HD-MSCs. PID-MSCs maintained the inhibitory effect on T- and B-lymphocyte proliferation, except for decreased inhibitory ability of SCID-MSCs at MSC:PBMC ratio 1:10. While HD- and CGD-MSCs were able to inhibit monocyte maturation into immature dendritic cells, in SCID- and WAS-MSCs this ability was reduced. After Toll-like Receptor priming, PID-MSCs displayed in vitro an altered gene expression profile of pro- and anti-inflammatory soluble factors. PID-MSCs displayed lower PPARγ levels and WAS- and SCID-MSCs higher levels of key osteogenic markers, as compared with HD-MSCs. Our results indicate that PID-MSCs may be defective in some functional abilities; whether these defects contribute to disease pathophysiology deserves further investigation.

Details

Title
Biological and functional characterization of bone marrow-derived mesenchymal stromal cells from patients affected by primary immunodeficiency
Author
Starc, Nadia 1 ; Ingo, Daniela 2 ; Conforti, Antonella 3 ; Rossella, Valeria 2 ; Tomao, Luigi 3 ; Pitisci, Angela 3 ; De Mattia, Fabiola 2 ; Brigida, Immacolata 2 ; Algeri, Mattia 3 ; Montanari, Mauro 3 ; Palumbo, Giuseppe 4 ; Merli, Pietro 3 ; Rossi, Paolo 5 ; Aiuti, Alessandro 6   VIAFID ORCID Logo  ; Locatelli, Franco 7 ; Bernardo, Maria Ester 8 

 Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy; Department of System Medicine, University of Rome “Tor Vergata”, Rome, Italy 
 San Raffaele Telethon Institute for Gene Therapy, SR-TIGET; Pediatric Immunohematology, San Raffaele Scientific Institute, Milan, Italy 
 Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy 
 Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy; Department of System Medicine, University of Rome “Tor Vergata”, Rome, Italy; University Department of Pediatrics, Unit of Immune and Infectious Diseases, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy 
 Department of System Medicine, University of Rome “Tor Vergata”, Rome, Italy; University Department of Pediatrics, Unit of Immune and Infectious Diseases, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy 
 San Raffaele Telethon Institute for Gene Therapy, SR-TIGET; Pediatric Immunohematology, San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy 
 Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy; Department of Pediatrics, University of Pavia, Pavia, Italy 
 Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy; San Raffaele Telethon Institute for Gene Therapy, SR-TIGET; Pediatric Immunohematology, San Raffaele Scientific Institute, Milan, Italy 
Pages
1-13
Publication year
2017
Publication date
Aug 2017
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1957218993
Copyright
© 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.